Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2023; 15(3): 410-418
Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.410
Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.410
Adherence to guideline-directed hepatocellular carcinoma screening: A single-center US experience
William W King, Raymond Richhart, Tyler Culpepper, Debdeep Banerjee, Nicole Ruiz, Jake Wilson, Ellery Altshuler, Department of Medicine, University of Florida, Gainesville, FL 32610, United States
Maneola Mota, Media Ismael, Joydeep Chakraborty, Virginia Clark, Roniel Cabrera, Department of Gastroenterology, University of Florida, Gainesville, FL 32610, United States
Michael Ladna, Walid Khan, Department of Hospital Medicine, University of Florida, Gainesville, FL 32610, United States
Author contributions: King WW conducted a plurality of this work; Mota M, Clark V, and Cabrera R developed the study concept and design; King W, Richhart R, Culpepper T, Mota M, Banerjee D, Ismael M, Chakraborty J, Ladna M, Khan W, Ruiz N, and Wilson J performed data acquisition; King W and Culpepper T performed statistical analysis; King W wrote the manuscript; Richhart R, Culpepper T, Altshuler E, Clark V, and Cabrera R assisted with revision and editing; Clark V and Cabrera R supervised this work.
Institutional review board statement: This research was approved by the Institutional Review Board of the University of Florida.
Informed consent statement: Informed consent was therefore not obtained from each individual patient. This process was approved by the institutional review board at the authors’ home institution, the University of Florida. Please contact the corresponding author with any questions or concerns.
Conflict-of-interest statement: The authors have no conflicts of interest.
Data sharing statement: De-identified patient data, study protocols, and statistical analysis protocols are available to be shared.
STROBE statement: STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: William W King, MD, Doctor, Department of Medicine, University of Florida, 1600 SW Archer Rd Room 4102, Gainesville, FL 32610, United States.
Received: November 11, 2022
Peer-review started: November 12, 2022
First decision: January 5, 2023
Revised: January 16, 2023
Accepted: February 21, 2023
Article in press: February 21, 2023
Published online: March 27, 2023
Processing time: 131 Days and 3.9 Hours
Peer-review started: November 12, 2022
First decision: January 5, 2023
Revised: January 16, 2023
Accepted: February 21, 2023
Article in press: February 21, 2023
Published online: March 27, 2023
Processing time: 131 Days and 3.9 Hours
Core Tip
Core Tip: This study reinforces existing knowledge that screening rates for Hepatocellular carcinoma are woefully inadequate, even in a subspecialty hepatology clinic. Unlike previous studies, ours identifies specific failure points, showing that screening failures are driven more by systemic issues than by physician or patient error.